Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts
Authors
Keywords
Cancer treatment, Pancreatic cancer, Phosphorylation, Signal inhibition, Diabetes mellitus, Cell proliferation, Drug therapy, Lentivirus
Journal
PLoS One
Volume 11, Issue 1, Pages e0147113
Publisher
Public Library of Science (PLoS)
Online
2016-01-14
DOI
10.1371/journal.pone.0147113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
- (2015) Sil Kordes et al. LANCET ONCOLOGY
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
- (2015) Hui Gao et al. NATURE MEDICINE
- Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma
- (2014) Robert J. Torphy et al. PLoS One
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation
- (2013) N. F. Neel et al. MOLECULAR CANCER THERAPEUTICS
- Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells
- (2013) Enza Lonardo et al. PLoS One
- Metformin improves healthspan and lifespan in mice
- (2013) Alejandro Martin-Montalvo et al. Nature Communications
- Metformin and Pancreatic Cancer: A Clue Requiring Investigation
- (2012) M. Pollak CLINICAL CANCER RESEARCH
- Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
- (2012) N. Sadeghi et al. CLINICAL CANCER RESEARCH
- Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells
- (2012) Weiguang Li et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- AMPK: a nutrient and energy sensor that maintains energy homeostasis
- (2012) D. Grahame Hardie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
- (2012) D. Soranna et al. ONCOLOGIST
- Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
- (2012) Michael N. Pollak Cancer Discovery
- AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets
- (2011) Ken Inoki et al. Annual Review of Pharmacology and Toxicology
- Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells
- (2011) B. Bao et al. Cancer Prevention Research
- Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
- (2011) I. Ben Sahra et al. CANCER RESEARCH
- The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
- (2011) Alejandro Vazquez-Martin et al. CELL CYCLE
- Targeting AMPK in the treatment of malignancies
- (2011) Eliza Vakana et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- AMP-activated protein kinase: nature's energy sensor
- (2011) David Carling et al. Nature Chemical Biology
- The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth
- (2010) Yin-Hsun Feng et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
- (2010) Marc Foretz et al. JOURNAL OF CLINICAL INVESTIGATION
- LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
- (2009) R. J. Shaw Acta Physiologica
- Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth
- (2009) K. Kisfalvi et al. CANCER RESEARCH
- New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes
- (2009) G. Libby et al. DIABETES CARE
- Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner
- (2009) R. Rattan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients
- (2008) B Rubio-Viqueira et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
- (2008) Walter H. Gotlieb et al. GYNECOLOGIC ONCOLOGY
- AMPK and Raptor: Matching Cell Growth to Energy Supply
- (2008) D. Grahame Hardie MOLECULAR CELL
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
- (2008) I Ben Sahra et al. ONCOGENE
- Metformin induces apoptosis of pancreatic cancer cells
- (2008) Luo-Wei Wang et al. WORLD JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search